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Abstract
The hypothalamic–pituitary–gonadal axis is of relevance in many processes related to the 
development, maturation and ageing of the male. Through this axis, a cascade of coordinated 
activities is carried out leading to sustained testicular endocrine function, with gonadal 
testosterone production, as well as exocrine function, with spermatogenesis. Conditions impairing 
the hypothalamic–pituitary–gonadal axis during paediatric or pubertal life may result in delayed 
puberty. Late-onset hypogonadism is a clinical condition in the ageing male combining low 
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concentrations of circulating testosterone and specific symptoms associated with impaired 
hormone production. Testosterone therapy for congenital forms of hypogonadism must be lifelong, 
whereas testosterone treatment of late-onset hypogonadism remains a matter of debate because of 
unclear indications for replacement, uncertain efficacy and potential risks. This Primer focuses on 
a reappraisal of the physiological role of testosterone, with emphasis on the critical interpretation 
of the hypogonadal conditions throughout the lifespan of the male individual, with the exception 
of hypogonadal states resulting from congenital disorders of sex development.
The hypothalamic–pituitary–gonadal (HPG) axis (FIG. 1) is of paramount importance in 
many processes related to the development, maturation and ageing of the male1. The 
pulsatile secretion of gonadotropin-releasing hormone (GnRH) by the hypothalamus 
stimulates the biosynthesis of gonadotropins (glycoprotein polypeptide hormones secreted 
by the anterior pituitary gland) — namely, luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH). LH (with gonadal testosterone and insulin-like factor 3 (INSL3)) sustains 
testicular endocrine function led by Leydig cells which is required for male genital 
development and differentiation throughout human sexual determination2. FSH, in turn, 
sustains testicular exocrine function led by Sertoli cells through spermatogenesis. The two 
Sertoli cell hormones, anti-Müllerian hormone (AMH) and inhibin B, participate in the 
regulation of genital masculinization and negative feedback regulation of FSH secretion, 
respectively. Likewise, the HPG axis has a key role in completing phenotypic differentiation 
and development of the fetus and male sexual maturation at puberty and into adulthood3.
Overall, congenital or acquired disturbances at any level of the HPG axis can lead to an 
impairment of reproductive function and the clinical syndrome of hypogonadism. Male 
hypogonadism is a disorder associated with decreased functional activity of the testes, with 
decreased production of androgens (steroid hormones that regulate male characteristics), 
inhibin B, AMH and/or impaired sperm production4. Hypogonadism can be caused by a 
primary testicular pathology (primary hypogonadism, otherwise known as 
hypergonadotropic hypogonadism) resulting from malfunction at the level of the testes due 
to a genetic cause, injury, inflammation or infection (BOXES 1,2). Conversely, 
hypothalamic and/or pituitary failures lead to secondary hypogonadism (also called central 
hypogonadism or hypogonadotropic hypogonadism), which is most often caused by genetic 
defects, neoplasm or infiltrative disorders (BOXES 1,2).
Signs and symptoms of hypogonadism depend on the age of onset, the severity of androgen 
deficiency and the underlying cause of androgen deficiency3. In healthy childhood, 
testosterone is low and spermatozoa are not produced; thus, decreased Sertoli cell function, 
as reflected by low inhibin B and AMH, is the cardinal sign of hypogonadism before 
puberty. Conditions impairing the HPG axis that occur during paediatric or pubertal life may 
result in delayed puberty (defined as the lack of sexual maturation by an age at which 95–
98% of the children have initiated sexual maturation)5,6. In adulthood, this can manifest as 
testosterone deficiency, which is a clinical syndrome resulting from reduced testicular 
testosterone production or from reduced serum testosterone activity, in conjunction with 
clinical signs and symptoms. Spermatogenic failure is usually included as a sign of 
hypogonadism. When specifically associated with ageing, obesity or poor health, adult-onset 
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hypogonadism is usually called late-onset hypogonadism (LOH). Depending on the causes, 
LOH can be persistent or potentially reversible (BOX 1).
This Primer focuses on a reappraisal of the physiological role of testosterone, with emphasis 
given to the critical interpretation of the hypogonadal conditions throughout the entire 
lifespan of the male, while considering as distinct the two periods of paediatric/pubertal and 
adult life in terms of both pathophysiology and clinical manifestations. Hypogonadal states 
resulting in congenital disorders of sex development fall outside the scope of this Primer.
Epidemiology
Pubertal hypogonadism
According to the age of onset, paediatric hypogonadism can manifest differently (BOX 3). 
Clinical presentation of hypogonadism at birth is rare, with abnormal genitalia occurring in 
~1 in 4,500 live births7. Hypogonadism established after birth, throughout childhood, is 
usually inapparent until pubertal age; at this point, the hypogonadal condition manifests as 
delayed puberty. The prevalence of delayed puberty in the general population has not been 
thoroughly assessed. In this context, it is important to note that the current definition of 
delayed puberty is statistical. In most textbooks and review articles, a cut-off of 14 years is 
cited; using this definition, early studies have found a prevalence of delayed puberty of <2% 
among boys in the United States8. However, the real prevalence is likely higher because 
transient forms (such as constitutional delay of growth and puberty (CDGP) or reversible 
forms of congenital isolated secondary hypogonadism) may remain undiagnosed. Delayed 
puberty is caused by CDGP in 60% of cases, secondary hypogonadism of organic origin in 
10% of cases, primary hypogonadism of organic origin in ~7% of cases or functional 
hypogonadism (both primary and secondary) in 20% of cases9–12. Some examples of 
paediatric and pubertal hypogonadisms of functional origin, which include chronic diseases 
and excessive drug use causing physiological suppression of the HPG axis, are listed in 
BOX 2 (REFS9–12). Type 1 diabetes mellitus is not usually associated with delayed puberty 
unless it is poorly controlled. However, in many of the chronic illnesses that can lead to a 
transient disorder, functional hypogonadism is rare, having an incidence between 1 per 
10,000 and 1 per 100,000 per year over childhood and young age13–16.
Secondary hypogonadism.—Secondary hypogonadism can be congenital or acquired 
(BOX 2). Congenital forms can present as isolated secondary hypogonadism, in which only 
GnRH and/or gonadotropins levels are affected, whereas the rest of the hypothalamic–
pituitary hormone axis remains intact. Congenital secondary hypogonadism is rare, having a 
global prevalence of 1 case per 4,000–10,000 boys17. Kallmann syndrome represents 60% of 
these forms and has been recognized to be familial (X-linked, autosomal dominant or 
autosomal recessive) or sporadic18. In addition to secondary hypogonadism, patients with 
Kallmann syndrome also present with hypo-anosmia (lack of smell) and malformations 
(such as midline defects, unilateral renal agenesis, bimanual synkinesia or mirror 
movements, syndactyly and dental agenesis)17.
Combined congenital secondary hypogonadism, is characterized by the deficiency of 
multiple pituitary hormones and results from a wide variety of even more rare genetic 
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conditions than isolated congenital hypogonadism, such as mutations of HESX1, PROP1, 
LHX3 and LHX4, which encode proteins involved in the HPG axis.
Acquired secondary hypogonadism could result from intracranial masses (such as 
craniopharyngioma) or infiltrative diseases (such as Langerhans cell histiocytosis) (BOX 2), 
both rare conditions, with a reported incidence of <5.0 per 1,000,000 per year, but 
characterized by a twofold higher prevalence during childhood than adulthood19,20. Other 
causes of acquired secondary hypogonadism are more typical in adult age. However, they 
can occur also in children and adolescents, delaying normal pubertal onset or progression. 
Of relevance, of boys with delayed puberty, the majority of cases are due to chronic diseases, 
such as hypothyroidism, growth hormone deficiency, Crohn’s disease and severe asthma9. 
Malnutrition is described in 3% of cases, whereas excessive exercise and anorexia nervosa 
as well as hyperprolactinaemia are less frequent in males9 (BOX 2).
Primary hypogonadism.—Klinefelter syndrome, a trisomy associated with a 47,XXY 
karyotype21,22, is the most important genetic cause of primary hypogonadism, with a global 
prevalence of 1 per 500–1,000 live male births23. A wide range of clinical manifestations 
characterize Klinefelter syndrome, but low testis volume and less often slow pubertal 
development are commonly reported, and primary hypogonadism develops almost 
universally by late adolescence (resulting in a delayed accomplishment of pubertal 
development) or early adulthood24. Of note, Klinefelter syndrome is frequently 
undiagnosed; indeed, as few as 25% of patients with Klinefelter syndrome are accurately 
diagnosed and most of these diagnoses are not made until adulthood25. Nevertheless, this 
may be changing with increased use of prenatal testing and increased use of karyotyping of 
comparative genomic hybridization array in evaluating boys with learning and/or 
behavioural issues.
Acquired causes of primary hypogonadism during childhood or puberty include 
chemotherapy and radiotherapy. For instance, alkylating agents are associated with a 
spermatogenesis failure in 80–90% of cases, which is irreversible in the majority of cases26. 
In ~10% of childhood cancer survivors, normal testosterone levels can be found with a 
normal development of secondary sexual characteristics26. After puberty, irradiation and 
chemotherapy may have even more severe adverse effects on testicular function.
Adult-onset hypogonadism
In healthy, young eugonadal men (defined as <30 years of age, with a normal testosterone 
production), serum testosterone levels range from 10.4 to 36.4 nmol/1 (300–1,050 ng/dl), 
with a slight gradual decline after 40 years of age27 (FIG 1). Using a serum total testosterone 
level <11 nmol/1 (317 ng/dl) to define biochemical hypogonadism, the Baltimore 
Longitudinal Study of Aging (BLSA) reported that ~12%, 20%, 30% and 50% of men in 
their 50s, 60s, 70s and 80s, respectively, are biochemically hypogonadal27. However, 
estimates regarding the prevalence of symptomatic hypogonadism vary widely. The 
European Male Ageing Study (EMAS) evaluated >3,000 men aged 40–79 years according to 
the combination of biochemistry (total testosterone level of <11 nmol/1 (317 ng/dl) and a 
free testosterone level of <0.22 nmol/1 (6.3 ng/dl)) and specific symptoms (presence of 
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erectile dysfunction, loss of morning erections and reduced sexual desire)28. Results showed 
an overall prevalence of 2.1 % in men aged 40–79 years and rates of 0.1% in 40–49 year 
olds, 0.6% in 50–59 year olds, 3.2% in 60–69 year olds and 5.1% in 70–79 year olds. Of 
note, 63% of men maintained physiological total testosterone (>11 nmol/1) levels into old 
age (70–79 years of age), suggesting that hypogonadism is not a uniform sign of ageing. 
Using only biochemical criteria, central hypogonadism was found in 11.8% of the EMAS 
cohort, with 2% having primary hypogonadism and 9.5% having ‘compensated 
hypogonadism’ (defined as high LH, with normal total testosterone), a condition not 
associated with clear symptoms of hypogonadism but that may be a potential harbinger of 
primary hypogonadism29,30. Hence, LOH is a relatively common condition in the ageing 
male (>40 years of age) — with a prevalence of 2–15% within the general population — and 
it is frequently associated with age-related comorbidities, such as obesity, metabolic 
syndrome and type 2 diabetes mellitus (T2DM)31,32.
Mechanisms/pathophysiology
The physiology of the HPG axis
An understanding of the role of the HPG axis throughout development, puberty and ageing 
and its role in male sex development is crucial in order to comprehend the pathophysiology 
of hypogonadism (FIG 2).
Infancy and childhood.—The initial differentiation of the testes in the embryo precedes 
the functional development of pituitary gonadotropins (BOX 4). At birth, gonadotropins and 
testicular hormone levels are low and increase during the first weeks and months of life33,34. 
Peak levels of LH, testosterone and INSL3 are reached during the third month4. Thereafter, 
serum gonadotropins and testosterone decline and remain low until the onset of puberty 
(FIG 2). During this relative physiological quiescence in childhood, basal gonadotropins and 
testosterone measurements do not reflect HPG axis function. Conversely, AMH and inhibin 
B levels increase progressively through infancy and remain high during childhood; their 
basal levels are most informative of Sertoli cell function4. Interestingly, the high androgen 
levels observed during fetal life and the postnatal period are not capable of inducing Sertoli 
cell maturation, full spermatogenesis and secondary sex characteristics as they do at puberty. 
The lack of androgen effect on Sertoli cells and spermatogenesis may be explained by the 
absence of androgen receptor expression in Sertoli cells over the first year of life. Indeed, the 
abnormal persistence of elevated testosterone beyond the first year results in signs of 
seminiferous tubule maturation (that is, a reduction in AMH and increase in inhibin B)35.
Puberty.—Puberty in boys begins with a progressive increase in the pulse amplitude and 
frequency of gonadotropin release36. FSH induces the proliferation of immature Sertoli cells 
and boosts testicular volume from 2 ml to 4 ml, the clinical landmark of pubertal onset that 
occurs at a mean age of 11.5 years37. Pubertal onset is considered delayed if it occurs 
between 14 years and 18 years of age, with the exact cut-off age depending on the 
considered guidelines38. LH induces a progressive increase in testicular androgen 
production; androgens together with FSH trigger Sertoli cell maturation. Consequently, 
Sertoli cell proliferation stops, AMH production declines and inhibin B secretion rises, as 
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seen in the initial stages of puberty (that is, stages 2 and 3 following the classic description 
by Marshall and Tanner39,40). The overt increase in serum testosterone levels is a later event, 
particularly marked during Tanner stages 3 to 5 (REF41). Germ cells undergo the complete 
spermatogenic process, leading to sperm production and to the overt increase in testis 
volume to 15–25 ml (FIG. 2) in Tanner stages 4 and 5. FSH and spermatogenesis are 
essential for inhibin B production, which in turn acts as a negative feedback regulator of 
pituitary FSH secretion42. Thus, in puberty and adulthood, inhibin B is an extremely 
informative biomarker of testicular function because it reflects the whole pubertal 
maturation process (for example, FSH and testosterone action on Sertoli cells and 
spermatogenesis)43.
Adulthood and ageing.—After puberty, in addition to their fundamental roles shown in 
terms of spermatogenesis1,44 and of male sexual function45, androgens have a variety of 
anabolic actions in the regulation of body composition, bone, muscle, glucose and lipid 
metabolism, erythropoiesis and cardiovascular and cognitive function over the entire 
lifespan46. Furthermore, several findings suggest that testosterone is neuroprotective and that 
declining testosterone levels during ageing are associated with cognitive and brain 
pathologies47. Ageing is characterized by a slow decline in testosterone levels with a 
substantial individual variability29,48–50; these age-related reductions in serum testosterone 
are mainly of primary origin in healthy men and are associated with both a loss of Leydig 
cells and their reduced ability to produce testosterone in response to LH51,52.
Apart from the deficiency of testosterone, hypogonadism also entails the deficiency of other 
testicular hormones (including INSL3, AMH and dihydrotestosterone (DHT)). As 
testosterone is a substrate for oestradiol synthesis, oestradiol production also decreases when 
testosterone levels decline. Hence, some of the symptoms associated with male 
hypogonadism may be due to suppressed oestrogen effects53. Among them, hypogonadal 
and/or ageing symptoms such as bone loss, osteoporosis, increased fat deposits and impaired 
sexual function may be even direct consequences of oestrogen rather than androgen 
deficiency.
Pubertal secondary hypogonadism
Secondary hypogonadism results from central defects of the hypothalamus or pituitary gland 
(BOX 2; FIG. 3).
The majority of patients with secondary hypogonadism, including those with Kallmann 
syndrome, respond to exogenous GnRH, pointing to a deficiency of endogenous GnRH as 
the important feature of their pathology54. A variety of LH secretory patterns can be 
observed in patients with congenital secondary hypogonadism. Although the majority have a 
complete absence of GnRH-induced LH pulses, some individuals have preserved sleep-
augmented LH secretion and others demonstrate enfeebled, low-amplitude LH secretion 
throughout the day and night55. Although congenital secondary hypogonadism has 
traditionally been regarded as a permanent condition, a considerable proportion of patients 
(~22%) in whom the diagnosis has been confirmed with repeated biochemical assessments 
spontaneously ‘reverse’ their reproductive function56,57. These patients undergo a 
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spontaneous amelioration of their disease by developing spontaneous GnRH-induced LH 
pulses, leading to spermatogenesis, in the absence of any fertility medications. Clinical58,59, 
laboratory60 and genetic61–63 characteristics of patients have been studied to identify 
prognostic phenotypic features for reversal, but identifying predictive characteristics has 
been difficult as reversal can occur even in the context of severe GnRH deficiency (that is, in 
those presenting with cryptorchidism, micropenis, absence of pubertal development or rare 
variants in a number of genes)57,64.
Genetic factors.—Over 35 loci have been implicated in the pathogenesis of congenital 
secondary hypogonadism. These loci can be loosely divided into two categories: genes 
encoding proteins that are involved in the development and migration of GnRH neurons and 
genes encoding proteins that are involved in the synthesis and secretion of GnRH itself (FIG 
4). The first gene associated with Kallmann syndrome was ANOS1 (an X-linked gene 
previously called KAL1), which encodes anosmin 1, an extracellular matrix protein that has 
a role in the guidance and migration of olfactory axons to the olfactory bulb65. Mutations in 
this gene cause a failed migration of GnRH neurons along the olfactory axons to the brain. 
Other genes associated with Kallmann syndrome encode proteins that work cooperatively 
with anosmin 1 (FIG. 4). For example, loss-of-function mutations in FGFR1 cause an 
autosomal dominant form of Kallmann syndrome65,66. Other genes, encoding proteins that 
amplify the GnRH secretory programme at puberty and modulate GnRH neuronal activity, 
are also associated with secondary hypogonadism by affecting GnRH secretion. Loss-of-
function mutations in KISS1 and KISS1R (encoding kisspeptin 1 and its receptor, 
respectively) have been associated with recessive forms of secondary hypogonadism67,68. 
Kisspeptin is expressed in the medial basal hypothalamus and is a powerful stimulus for 
GnRH-induced LH secretion in mammalian species6,69. Although a powerful stimulus for 
GnRH secretion, kisspeptin seems to be just one part of an intricate network of 
hypothalamic neuropeptides that regulate GnRH release. Mutations in the genes encoding 
neurokinin B and its receptor (TAC3 and TACR3, respectively) have also been identified in 
patients with secondary hypogonadism70. Neurokinin B can stimulate LH secretion in some, 
but not all, physiological settings and may have an important role in modulating GnRH pulse 
frequency71.
Discovery of causal genetic variants for Kallmann syndrome led to greater understanding of 
the heritability of delayed puberty and the timing of puberty within the healthy population. 
Patients with delayed puberty are more likely than control subjects with normal pubertal 
timing to carry potentially pathogenetic variants in genes associated with secondary 
hypogonadism genes72. Moreover, delayed puberty probands seem enriched for rare variants 
in TAC3 or TACR3 as compared with controls. This observation suggests that delayed 
puberty and secondary hypogonadism with reversal sit on the same phenotypic and genetic 
spectra. Further supporting the important role of neurokinin B in reproduction, a common 
variant near TACR3 has been shown to be associated with variation in the normal timing of 
female puberty73,74.
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Late-onset hypogonadism.—In principle, testicular function continues after puberty 
uninterrupted until old age. Men have no abrupt decrease in testosterone production 
comparable to menopause in women. However, epidemiological studies have demonstrated a 
0.5–1.5% per year decrease in circulating total testosterone concentrations and a 2–3% per 
year decrease in free testosterone concentrations in community-dwelling middle-aged to 
older men beyond the age of ~30 years27,28,75–77. The difference between the decline of total 
testosterone and free testosterone over the ageing process is explained by the age-related 
increase in circulating concentration of sex hormone-binding globulin (SHBG), which 
reduces the proportion of free testosterone78. In healthy men, the age-related decline of 
testosterone is accompanied by an increase in LH, indicating that it is mainly caused by a 
primary testicular failure compensated for by an increased LH secretion (FIG. 5). The age-
related decrease in testosterone apparently reflects general age-related cellular degeneration, 
reduced number of functional Leydig cells and atherosclerosis of testicular arterioles75. 
Nevertheless, in most men, testosterone production remains well within the reference range 
of young individuals, and, if there are no hypogonadal symptoms, the decline is apparently 
clinically nonsignificant.
Many men gain weight and acquire chronic diseases with ageing; both conditions are also 
associated with decreased testosterone levels79 (FIG. 5). In the EMAS, 73% of men with 
reduced testosterone were overweight or obese, and serum testosterone of men with a body 
mass index (BMI) >30 kg/m2 was 5 nmol/l (144ng/dl) lower than for those with normal 
weight28. Furthermore, a 4.5-year longitudinal arm of the EMAS80, as well as a meta-
analysis81, demonstrated that weight gain suppresses and weight loss increases testosterone 
level. In these situations, the suppression of testosterone production is of the secondary type 
(that is, not accompanied by increased LH secretion but rather caused by decreased activity 
at the hypothalamic–pituitary level). It is also apparent that obesity (and chronic diseases) 
suppresses testosterone production rather than the opposite82. In real life, suppressed 
testosterone of ageing men emerges as the combined effect of ageing, obesity and 
comorbidities. Of further note, obesity mainly suppressed total testosterone, with less effect 
on free testosterone, because of an accompanying decrease in SHBG. Hence, symptomatic 
hypogonadism, apart from a biochemical reduction in total testosterone, is less common in 
otherwise healthy obese men83.
The exact cause of secondary hypogonadism in men with obesity with suppressed 
gonadotropin secretion is still not completely understood. In this context, the obesity-related 
suppression of HPG function has several possible mechanisms. These mechanisms include 
the pleiotropic inhibitory effects of adipocyte-produced adipokines, cytokines and 
chemokines on GnRH and gonadotropin secretion84 as well as obesity-related central insulin 
resistance85, which may negate the stimulatory effect of insulin on gonadotropin secretion. 
One of the candidate peptides is fat-cell-produced leptin86. Such a link is suggested by the 
observed decreasing effect of testosterone treatment on leptin levels in men87. Adequate 
leptin concentrations are needed for a normal function of the HPG axis, and in obesity cases 
with high leptin levels, the resistance to this hormone may explain the mechanism for its 
tenuous involvement in obesity-associated secondary hypogonadism88,89. The mechanisms 
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of leptin resistance entail its limited access at the blood–brain barrier to the central nervous 
system90, defects in leptin receptor signalling89 and hypothalamic endoplasmic reticulum 
stress91. Other adipokines such as the pro-inflammatory fat tissue cytokines (for example, 
tumor necrosis factor, IL-2 and IL-6)92,93 might also suppress gonadotropin secretion, in 
addition to central nervous system endocannabinoids94, central insulin resistance95 and 
adiponectin96.
By contrast, the long-held hypothesis of involvement of increased adipose tissue oestrogen 
production, through increased feedback inhibition of GnRH secretion, may not hold true in 
light of newer findings29. Serum oestrogen concentrations are in fact low in obese men29 
and high only in morbidly obese men (defined by BMI >40 kg/m2)97,98. It was recently 
demonstrated that hyperinsulinaemia alongside elevated serum lipid levels suppresses 
gonadotropin secretion directly at the pituitary level, providing an additional candidate 
mechanism for the obesity-associated secondary hypogonadism99. Finally, the low SHBG 
values associated with obesity might lower the set point of the hypothalamic–pituitary 
feedback inhibition in relation to circulating total testosterone. Because mainly total 
testosterone, and to a lesser extent free testosterone, is suppressed in obese men, negative 
feedback inhibition of gonadotropins can be achieved at a lower level of circulating total 
testosterone.
Diagnosis, screening and prevention
Diagnosis of prepubertal hypogonadism
Disorders of sex development and treatment of neonatal hypogonadism are not the focus of 
this Primer; however, the dramatic changes taking place in the HPG axis during fetal and 
postnatal development (BOX 4) require special consideration in the diagnostic approach of 
male hypogonadism in later paediatric ages.
Paediatric and prepubertal hypogonadism.—After the third to sixth month of age, 
serum gonadotropins and testosterone normally decline (FIG. 2); thus, they are no longer 
informative for the diagnosis of central hypogonadism33. In this period of life, only AMH 
and inhibin B determinations may be helpful: low serum AMH and inhibin B in a boy with 
non-elevated gonadotropins point to secondary hypogonadism41 (TABLE 1). As detailed, 
elevated gonadotropins are indicative of primary hypogonadism. However, up to one-third of 
boys with complete absence of testicular tissue have normal FSH and LH in childhood, 
showing that primary hypogonadism is not always associated with high gonadotropin levels 
in childhood100.
When established during childhood, clinically evident symptoms are limited. As a result, 
secondary hypogonadism or primary hypogonadism may go undiagnosed unless Sertoli cell 
function is assessed101 (TABLE 1) Viable trisomies (chromosomal disorders characterized 
by additional chromosomes), such as Klinefelter syndrome and Down syndrome, are the 
most frequent causes of primary hypogonadism (TABLE 1). Gonadal dysfunction is present 
from early childhood in most boys with Down syndrome102, whereas it usually emerges 
during mid-puberty in patients with Klinefelter syndrome103.
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Hypogonadism in pubertal age.—Most boys have initiated pubertal development by 
the age of 14 years. The lack of pubertal signs by this age should prompt diagnostic 
evaluation (FIG. 6). In approximately two-thirds of cases, delayed puberty represents an 
extreme of the normal spectrum of pubertal timing (that is, CDGP)3. Family history may be 
informative: delayed puberty followed by spontaneous onset in a parent or sibling suggests 
CDGP, whereas a history of anosmia and/or hyposmia points to Kallmann syndrome104. In 
delayed puberty, stature is short for chronological age but adequate for bone age, which is 
typically delayed in CDGP. Chronic disease, medication use, inadequate nutritional status or 
psychosocial condition, which all can lead to functional hypogonadism105, should also be 
ruled out. Primary hypogonadism105 is easily diagnosed by the presence of elevated 
gonadotropins. On the other hand, the differential diagnosis between persistent secondary 
hypogonadism, responsible for ~10% of cases, and CDGP may prove extremely difficult. 
Basal gonadotropin levels may be informative only to rule out, but not to confirm, secondary 
hypogonadism103, and although there is no unequivocal agreement on their usage, dynamic 
tests with native GnRH or its agonists can be considered106. A large number of different 
tests have been described, but none of them can ascertain the diagnosis without pitfalls 
because a prepubertal response may be observed in patients with CDGP in whom the HPG 
axis has not yet been reactivated105. It is worth mentioning that secondary hypogonadism 
with partial pubertal development is particularly difficult to distinguish from CDGP. The 
concomitant measurement of serum inhibin B may be helpful: low levels are indicative of 
hypogonadism whereas normal levels suggest CDGP107 (TABLE 1). Of relevance, adults 
with idiopathic secondary hypogonadism may have normal inhibin B levels. MRI is 
performed when central nervous system lesions are suspected, when delayed puberty is 
extreme or in patients with anosmia and/or hyposmia to demonstrate evidence of olfactory-
bulb aplasia and/or hypoplasia and to support the diagnosis of Kallmann syndrome105. 
Genetic testing is becoming more widely available and may be useful for diagnosis, 
prognosis108 and genetic counselling, although the utility may be limited by the variable 
penetrance and expression associated with many genetic causes of idiopathic secondary 
hypogonadism109. Comparative genomic hybridization array identifies large deletions or 
insertions, and candidate gene screening or next-generation sequencing are used to unveil 
point mutations in >30 genes known to be implicated in central hypogonadism following 
monogenic or multigenic patterns110.
Diagnosis and screening in adults
According to most international scientific societies, the mainstay of an LOH diagnosis 
includes the presence of signs and symptoms consistent with hypogonadism coupled with 
low morning serum testosterone levels on two or more occasions as measured with a reliable 
method28,45,111–113. However, the constellation of symptoms commonly associated with 
LOH in adult men can be diverse and nonspecific and often mimics several systemic 
conditions, including obesity, metabolic syndrome and even the normal ageing process114. 
In addition, the exact cut-off values to define low testosterone levels differ depending on the 
society guidelines (TABLE 2). For a relatively large number of hysicians involved in the 
diagnosis and therapy of LOH, as well as in the translational research dedicated to LOH, the 
clinical practice guidelines first published in 2010 and recently updated by the Endocrine 
Society in 2018 are the most widely accepted procedures for the diagnosis and treatment of 
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hypogonadism; however, adherence to these guidelines remains poor45,111,112. Thus, with a 
lack of a universally accepted protocol (TABLE 2), inconsistent and improper case 
management of LOH patients in many clinical settings has been observed114–116.
Signs and symptoms.—The symptoms of low testosterone in adult males can be 
difficult to diagnose. Given the myriad of pathways affected by the HPG axis and the 
potentially slow progression of symptoms, LOH signs may include a wide range of clinical 
presentations, including loss of libido, erectile dysfunction, depression, lethargy, anaemia 
and loss of muscle and bone mass111–113,117–119. At present, questionnaire-based scoring 
systems on LOH symptoms are not reliable enough because of their poor specificity and 
they are required to be followed-up with confirmatory serum testosterone testing and never 
used in isolation for making a diagnosis of hypogonadism45,113,120.
Serum testosterone measurements.—Testosterone measurements (taken between 
7:00 and 11:00 am) in the fasting state are recommended45,111–113,120 (FIG. 1). Mass 
spectrometry is the gold standard of testosterone assays, but good-quality immunoassays 
provide fully acceptable results for clinical diagnosis121.
A lack of consensus exists regarding an absolute testosterone level indicative of LOH 
(TABLE 2). A practical definition of biochemical LOH uses cut-off concentrations of total 
testosterone in the range of 9.0–9.5 nmol/1 (260–275 ng/dl). Use of this value to define 
hypogonadism is supported by a randomized controlled trial (RCT) showing that 
testosterone treatment improves symptoms in several domains of sexual function in men 
with morning total testosterone <9.1 nmol/1 (262 ng/dl)117; conversely, another trial with a 
total testosterone threshold of 10.4nmol/l (300ng/dl) did not find improvement of sexual 
function122.
The most recent update of the Endocrine Society guidelines indicates a lower limit threshold 
for total testosterone harmonized to the US Centers for Disease Control and Prevention 
standard in healthy nonobese young men of 9.2 nmol/1 (264ng/dl), whereas the guidelines 
did not indicate any thresholds for free testosterone owing to the lack of harmonized 
accepted criteria112. The same authors recognized that free testosterone should be measured 
by an equilibrium dialysis method and that until a harmonized reference range is established, 
the lower limits indicated by the laboratory method may be used111,112 (TABLE 2). 
According to the EMAS, the most specific diagnosis of LOH is reached if, in addition to 
total testosterone and free testosterone levels below the defined threshold concentrations 
(that is, <11 nmol/l and <220 pmol/l, respectively), three sexual symptoms should be present 
(more specifically, erectile dysfunction, reduced morning erections and diminished sexual 
thoughts)28.
If low total testosterone is observed, a second total testosterone test should be administered 
to confirm the diagnosis45,111,112. Clinicians should exercise caution when using total 
testosterone testing in men who are elderly or obese or who have diabetes as these 
conditions modulate the level of SHBG and, therefore, may overestimate or underestimate 
serum bioactive testosterone levels111–113,123,124 (FIG. 1). In these selected patients, testing 
for free testosterone or bioavailable testosterone is suggested, although bioavailable 
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testosterone is not unanimously recommended by all guidelines111,112. In the case of free 
testosterone, ligand displacement immunoassays have been criticized and are currently not 
recommended as they are influenced by SHBG and are inaccurate111,112. The most accurate 
method of measuring free testosterone is equilibrium dialysis, but calculating free 
testosterone using total testosterone, SHBG and albumin levels and one of the algorithms 
(for example, the equation of Vermeulen et al.111,112,125) provides a sufficiently accurate 
estimate for clinical practice, although it has not met consensus126,127. The latest findings 
indicate that measurement of free testosterone (direct or calculated) improves the diagnostic 
accuracy of symptoms, especially in obese men83,113,123,128.
Following confirmation of low serum testosterone levels and concomitant signs and 
symptoms of hypogonadism28,45,113, providers should use serum LH and FSH in 
conjunction with testosterone to differentiate between primary and secondary 
hypogonadism29.
Additional analyses.—If LOH is suspected, clinicians need to comprehensively exclude 
acquired causes (BIX 2). Often, obesity maybe the main causative factor of LOH. Additional 
laboratory tests and imaging techniques can be used to define the diagnosis. For patients 
suspected of primary hypogonadism, routine semen analysis and testicular sonography are 
examples of specialized diagnostic practices that can aid in confirming a diagnosis and 
localizing a lesion or specific area of testicular dysfunction129,130. Conversely, in the case of 
suspected secondary hypogonadism, laboratory tests such as serum prolactin levels, iron 
saturation and pituitary function tests can assist in identifying causes of hypothalamic and/or 
pituitary dysfunction. Pituitary contrast-enhanced MRI or CT may be indicated to exclude a 
pituitary adenoma or other lesions of the hypothalamic-pituitary region45,111–113,130–132. 
Defining the aetiology is important as it might influence management. Indeed, if, for 
instance, hyperprolactinaemia emerges as the cause of hypogonadism, the condition of 
hypogonadism needs to be differently managed using dopamine agonist therapy131.
Screening.—Screening for hypogonadism in adult men is still an area of heavy 
debate45,111,112. For instance, the Endocrine Society’s guidelines recommend against any 
form of screening in the general population127, except in patients with diabetes and bone 
fractures. Conversely, Endocrine Society guidelines along with the European Association of 
Urology (EAU), the International Society for Sexual Medicine (ISSM) and the British 
Society for Sexual Medicine (BSSM) guidelines suggest screening adult men with sexual 
dysfunction45,113,120, including those with reduced sexual desire and sexual activity, erectile 
dysfunction and fewer and diminished nocturnal erections (Level of Evidence (LoE) 1, grade 
A)113.
Management
In general, secondary hypogonadism is characterized by low or inappropriately normal 
gonadotropin levels; thus, the rationale is to substitute the gonadotropin deficiency with FSH 
and LH if fertility is desired133,134. If fertility is not an issue, testosterone therapy is advised. 
By contrast, when there is testicular damage, the condition is termed primary, and the only 
rational therapy is testosterone therapy. Testosterone therapy for congenital forms of 
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hypogonadism must be lifelong; management of acquired causes depends on whether the 
condition is permanent or can be resolved, but testosterone treatment of LOH remains a 
matter of debate.
Paediatric and pubertal hypogonadism
The focus of this section is on the management of delayed puberty; the management of 
disorders of sex development and neonatal hypogonadism are reviewed elsewhere135,136. It 
should be noted that trials comparing different treatment regimens are lacking in delayed 
puberty; thus, the recommendations below are based, in part, on expert opinion and do not 
include all potential regimens.
CDGP.—Management of CDGP is often limited to reassurance, adult height prediction and 
expectant observation, particularly if puberty has started clinically and/or biochemically, but 
therapy with low-dose testosterone can be used as well104,105,137,138 (BOX 5). If medication 
is initiated, it is usually to assuage psychosocial difficulties that derive from negative 
interactions with peers, decreased self-esteem and anxiety about growth rate and/or body 
habitus.
A short course of low-dose testosterone in boys with CDGP can lead to increased growth 
velocity, initiation of secondary sexual characteristics and positive effects on psychosocial 
well-being without considerable adverse effects, rapid advancement of bone age or reduced 
adult height139,140. Testosterone esters given by intramuscular injection are the mainstay of 
treatment. A common protocol is to initiate supplementation with testosterone enanthate or 
cypionate each month for 3–6 months, which can be repeated for another 3–6 months with 
dose escalation if evidence of spontaneous puberty is lacking (BOX 5). However, 
intramuscular injections are painful and may require frequent health-care visits for 
administration. Moreover, intramuscular injections result in levels of serum testosterone that 
lack diurnal rhythm and are characterized by non-physiological peaks and troughs, although 
it is still unclear whether this is clinically significant. Hence, there is interest in alternative 
approaches, including use of subcutaneous testosterone injections141, oral androgens such as 
testosterone undecanoate10 and transdermal testosterone gels142,143, including a nasal gel 
that decreases the risk of person-to-person medication transfer144. Novel therapies such as 
synthetic kisspeptin are also being explored5,145. Although some of these agents are 
promising, additional data and experience are needed before these alternatives can be 
recommended for routine management of CDGP in place of testosterone esters.
For a subset of patients, short stature can be more concerning than delayed puberty, and 
CDGP is considered by some to be a subgroup of idiopathic short stature (ISS). Although 
growth hormones are approved for the treatment of ISS in many countries, this therapy has 
at best a modest effect on adult height in adolescents with CDGP and its routine use is not 
recommended. In boys with CDGP and short stature, another potential therapeutic approach 
is aromatase inhibition146,147. Aromatase inhibitors inhibit the conversion of androgens to 
oestrogens, the predominant hormone responsible for epiphyseal closure, raising the 
possibility that aromatase inhibitors could prolong growth and increase adult height. 
Recently, the use of aromatase inhibitors to promote endogenous puberty in boys with 
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CDGP has also been reported148. However, the amount of height gained as well as the 
optimal timing, dose and duration of aromatase inhibitor treatment remain uncertain; 
moreover, potential adverse effects must be considered, and this treatment also requires 
further study before it should be incorporated into routine practice146,147.
Persistent hypogonadism.—In boys with persistent primary or secondary 
hypogonadism, initial testosterone therapy is the same as for CDGP (BOX 5), but doses are 
gradually increased to full adult replacement levels over ~3 years to allow development of 
secondary sexual characteristics. In cases of known defects, therapy can be initiated at 
younger ages that are more typical for pubertal initiation rather than waiting for an 
individual to have confirmed delayed puberty. When the differentiation of CDGP from 
persistent secondary hypogonadism is uncertain, time is often the defining variable; if 
spontaneous puberty has not occurred after 1 year of treatment, doses of testosterone can be 
gradually advanced towards adult levels while monitoring endogenous puberty (examination 
of testicular size and measurement of LH, FSH and testosterone) every 6 months.
Exogenous testosterone does not induce testicular growth or spermatogenesis, and initiation 
of spermatogenesis is often not possible in those with testicular defects. Induction of fertility 
in secondary hypogonadism requires treatment with pulsatile GnRH and/or exogenous 
gonadotropins (BOX 5). Over the past several years the use of gonadotropins and/or GnRH 
to induce puberty has garnered increasing interest. Many questions have been identified. Are 
fertility outcomes better if FSH is administered before administration of human chorionic 
gonadotropin (hCG)? Would FSH pretreatment versus GnRH administration alone improve 
outcomes, especially for those with the smallest testes? Is GnRH administration superior to 
gonadotropin therapy? Perhaps most important for adolescents is the question of whether 
fertility outcomes would be improved if GnRH and/or gonadotropins were used to induce 
puberty instead of waiting to administer these agents in adulthood104,137,138,149,150. For the 
last question, more research is needed before such therapies are routinely recommended for 
pubertal induction in place of the less invasive and less expensive use of testosterone. 
Regardless of the treatment regimen used, it is important that the care of these patients be 
transferred successfully from paediatric care to adult care providers.
Hypogonadism in adults
The management of genetic secondary hypogonadism depends on the type of the underlying 
disease and on patients’ needs. In adulthood, when fertility is required, the most widely used 
compound is injected hCG (intramuscular or subcutaneously) weekly, alone or in 
combination with FSH weekly. In men, the recombinant preparations seem not to offer 
significant advantages when compared with the purified compounds, derived from the urine 
of either pregnant or postmenopausal women151. Fertility can also be induced using GnRH 
administered in a pulsatile manner, but this treatment is not widely available151. Conversely, 
the use of anti-oestrogens is useless and even contraindicated in these individuals133.
Men with genetic disorders.—In males with Klinefelter syndrome, the degree of 
androgen deficiency depends on the number and residual function of Leydig cells; 
spontaneous fertility is rarely observed152. Likewise, even among men with Klinefelter 
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syndrome, hypogonadism is associated with greater risk of metabolic syndrome, T2DM, 
cardiovascular disease (CVD), breast cancer and extragonadal germ cell tumours25.
Testosterone replacement therapy is the mainstay of treatment in hypogonadal patients with 
Klinefelter syndrome; however, randomized trials are needed to determine optimal 
therapeutic regimens and subsequent follow-up schedules22. Although the degree of 
virilization as well as the levels of testosterone are usually normal at puberty in boys with 
Klinefelter syndrome, some evidence has suggested that an early treatment with testosterone 
should be offered to the majority of patients, starting from the peri-pubertal period, to ensure 
an optimal development of sexual characteristics, muscle bulk and bone structure and to 
prevent the long-term negative consequences of hypogonadism, including metabolic diseases 
and mental impairment153. However, available data on this topic are conflicting and are 
largely based on nonrandomized studies. An age-dependent decline in testosterone is 
reported with a high prevalence of hypogonadism detected in adulthood154,155. Hence, 
testosterone therapy in Klinefelter syndrome should be offered in the presence of 
documented reduced levels of total testosterone (<12 nmol/1 (<3.5ng/ml)) associated with 
symptoms, in adulthood, or earlier as a consequence of delayed puberty152,153.
Infertility in men with Klinefelter syndrome had long been considered an untreatable 
condition. Recent data have emphasized that individuals with Klinefelter syndrome may 
benefit from assisted reproductive techniques owing to the presence of residual foci of 
preserved spermatogenesis within the testis. Accordingly, a recent meta-analysis of the 
available data has documented that testicular sperm extraction can be successful in almost 
50% of individuals with Klinefelter syndrome, with a subsequent live birth rate close to 
50%156. All these results seem to be independent of any clinical or biochemical parameters 
tested156 or the age at which surgery was performed157.
Late-onset hypogonadism.—In contrast to testosterone therapy for congenital forms of 
hypogonadism, which has to continue throughout the lifespan of the man, testosterone 
treatment of LOH is controversial because of unclear indications for replacement and 
potential risks in older individuals that have been widely and often harshly debated without a 
definitive conclusion45,158. Ageing men may develop low testosterone mainly owing to 
being overweight, inactive and having chronic diseases28,45. The first advice for these 
patients is to address modifiable risk factors — if present — and to improve lifestyle through 
exercise, reducing weight and good treatment balance of comorbidities80,159–161. These 
modifications may result in serum testosterone level improvement (although it may not 
become fully normalized) and reduce associated symptoms and health risks159. Moreover, in 
real life, lifestyle modification may be difficult; thus, the pharmacological reversal of 
reduced testosterone levels has been promoted as an alternative. Indeed, low testosterone is a 
biomarker for impaired general health, and treatment of comorbid conditions is important in 
combination with testosterone therapy45,46,49,162. Overall, it is necessary to underline how 
the debate related to testosterone therapy in men with clinical and biochemical 
characteristics suggestive of LOH is still continuing. In this context, the principle of 
testosterone therapy is based on the assumption that low testosterone levels are the cause 
(that is, risk factor) of the hypogonadism-associated symptoms rather than their 
consequence. Although the causality is definitely bidirectional, evidence is mounting that 
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low testosterone is primarily the consequence (that is, risk marker) of ill health rather than 
its cause80,81. Thus, testosterone therapy, aimed at treating symptoms associated with low 
testosterone and improving quality of life in LOH, remains controversial without a definitive 
and unanimously accepted conclusion120. Indeed, although improvement of symptoms is 
often observed, unclear indications for replacement, the optimum serum testosterone levels 
and potential risks (especially cardiovascular risk) in older individuals have led to 
conflicting recommendations by societies, as outlined below. The most worrying gap in our 
knowledge at the moment is the paucity of information on potential long-term effects, both 
positive and negative. To this aim, we also discuss recommendations in terms of follow-up 
and contraindications for treatment.
As detailed, common symptoms in men with low testosterone are sexual dysfunction; less 
specific conditions associated with low testosterone, including unexplained anaemia, 
osteoporosis, loss of vigour, frailty, insomnia, cognitive dysfunction and depression, have 
been described, although these symptoms may occur also in older men with normal serum 
testosterone levels and on their own seldom justify the diagnosis of LOH120. Recently, RCTs 
have advanced our knowledge on indications for testosterone therapy45,113,117,120,163: sexual 
symptoms may improve, including erectile dysfunction and loss of libido. For patients with 
T2DM and erectile dysfunction, this was only the case in men with clearly reduced 
testosterone levels (<8 mmol/1 (2.31 ng/ml))164. From a pathophysiological standpoint, it 
has been argued that this is because erectile dysfunction in T2DM is predominantly due to 
vascular and neuropathic disease and is, therefore, not likely to be the case in those men who 
do not have an established vascular disease.
The Birmingham, Lichfield, Atherstone, Sutton Coldfield, and Tamworth (BLAST) RCT 
showed that the administration of injectable testosterone undecanoate or placebo for 30 
weeks to hypogonadal men with T2DM promoted a significant reduction in glycated 
haemoglobin (HbA1c) in testosterone-treated patients compared with placebo-treated men at 
6 weeks and 18 weeks, but not at 30 weeks165. Among non-depressed men, those treated 
with testosterone undecanoate had significant improvements in BMI, weight, waist 
circumference, erectile function scores and Aging Males’ Symptoms (AMS) scores165. The 
Testosterone Replacement in Hypogonadal Men with Type 2 Diabetes and/or Metabolic 
Syndrome (TIMES2) trial evaluated symptomatic hypogonadal men treated with 
testosterone gel or placebo for 12 months166. At 6 months, testosterone-treated patients had 
reduced insulin resistance (assessed by the homeostasis model assessment of insulin 
resistance (HOMA-IR)) compared with placebo-treated patients, reduced lipo-protein A 
(Lpa), reduced high-density lipoprotein (HDL) and improved erectile function scores, 
although no improvements of HbAlc levels were observed. Among participants with 
metabolic syndrome, testosterone therapy reduced Lpa and low-density lipoprotein (LDL) 
compared with placebo166. Hence, although testosterone treatment of men with LOH has in 
some studies shown modest improvement in glycaemic control, such data overall are 
inconsistent. The current evidence is insufficient to support testosterone therapy to improve 
the metabolic status in older men with LOH or in particular those with T2DM or the 
metabolic syndrome. The recent Endocrine Society guidelines support this conclusion112.
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One of the hallmarks of male hypogonadism is osteoporosis. Testosterone treatment of 
hypogonadal men has been shown to bring about variable increases in areal and volumetric 
bone mineral density in lumbar, spinal, vertebral and femoral neck regions167–169. In 
general, the magnitude of the treatment effect is inversely related to basal serum 
testosterone118. Unfortunately, information about treatment response of the most important 
clinical end point (that is, fracture prevention) is completely missing. Expert opinions 
consider the specific anti-resorptive treatments and osteoanabolic agents effective in 
preventing bone loss in hypogonadal men170,171. Testosterone treatment as monotherapy for 
osteoporosis is recommended only in hypogonadal men in whom there are contraindications 
for approved anti-resorptive therapies. Nevertheless, testosterone may have a modest positive 
effect on bone health in men whose testosterone treatment has been initiated for other 
reasons.
An additional common sign of hypogonadism in ageing men is unexplained anaemia. 
Convincing data exist that this symptom responds favourably to testosterone 
treatment172,173, even to the extent that polycythaemia is a common adverse effect of the 
therapy and must be carefully controlled. However, in the Testosterone Trials (TTrials), the 
average increase in haemoglobin by 10g/l was not found to be associated with clinically 
significant improvements of physical performance173.
Numerous studies also suggested an association between serum testosterone levels and 
depressive symptoms174. However, the relationship between low testosterone and depression 
seems to be complex and associated with many factors, such as androgen receptor genetic 
polymorphisms175,176. A registry study of 762 hypogonadal men found that 92.4% of men 
demonstrated some level of depressive symptoms, with 17.3% of men having moderately 
severe to severe depressive symptoms174. After 12 months of testosterone therapy, the 
percentage of patients with moderately severe to severe symptoms decreased from 17.3% to 
2.1 %174. In the Vitality Trial, there were significantly greater improvements between the 
testosterone therapy group and the placebo group in the 36-Item Short-Form Health Survey 
(SF-36) vitality score (mean difference 2.41 points; P=0.03) and the Patient Health 
Questionnaire 9 (PHQ-9) depression score (mean difference −0.72 points; P=0.004)117. 
More recently, findings from a meta-analysis aimed at assessing the association of 
testosterone treatment with depressive symptoms in men showed a moderate antidepressant 
association of testosterone treatment translatable into a clinically relevant symptom 
reduction119. This effect was confirmed only in men with hypogonadism and in those having 
more subtle symptoms of depression. However, the large portion of studies with high or 
unclear risk of bias and the low number of methodologically rigorous RCTs primarily 
addressing the effect of testosterone treatment in depressed but otherwise healthy men limit 
the interpretation, as per the admission of the authors. Considering all available information, 
testosterone treatment of men with LOH may have a slight improving effect on mood, but 
there is no convincing evidence suggesting that testosterone therapy could be used to treat 
depression of older men. Other mental well-being symptoms of LOH, such as cognitive 
dysfunction, did not significantly improve under testosterone therapy compared with 
placebo177.
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Recently, findings from the Physical Function Trial, one of the of seven TTrials, 
demonstrated that testosterone therapy consistently improved self-reported walking ability in 
men >65 years of age and modestly improved 6-minute walk test distance but did not affect 
falls178. The effect of testosterone on mobility measures was related to baseline gait speed 
and self-reported mobility limitation and changes in testosterone and haemoglobin 
concentrations178.
Although there are as yet insufficient data to define optimal serum levels of testosterone 
during testosterone therapy, the aim is to restore serum testosterone to physiological 
levels45,112,113,120, and most of the scientific societies suggest they aim at achieving 
testosterone concentrations in the mid-normal range during treatment with any of the 
approved formulations, usually taking into consideration the patient’s preference as the 
criterion of choice of preparation after having involved the patient in decision-making and 
the potential benefits and risks of therapy have been discussed45,112,113,120. Several 
applications of testosterone are available for testosterone therapy, induding oral preparations, 
transdermal gels and intramuscular injections. Truly comparative studies of different 
applications are not available45,120.
Testosterone therapy is associated with a number of possible adverse events, including an 
increase in red blood cells and an elevation of prostate-specific antigen (PSA)112. Although 
observational studies do not indicate a higher risk of thrombosis or prostate cancer in men 
undergoing testosterone therapy, monitoring remains highly advisable112,113,120,179,180. As a 
whole, serious adverse events related to testosterone therapy are relatively rare. Overall, they 
are more significant in elderly patients and are often dependent on the method of delivery. 
Some adverse events are related to supraphysiologic levels and can be lowered or stopped 
altogether by adjusting the dose or switching to a different formulation113.
In terms of treatment follow-up, it is strongly recommended to perform haematological, 
cardiovascular, breast and prostatic assessment before the start of 
treatment45,112,113,120,179,180. After testosterone therapy has been established, it is suggested 
to assess the response to testosterone treatment at 3 months, 6 months and 12 months after 
the onset of treatment and thereafter annually45,112,113,120,179,180. This assessment includes 
monitoring haematocrit (haematocrit levels should remain <54%), haemoglobin, testosterone 
values and PSA during testosterone treatment. Men with CVDs should be monitored 
carefully throughout the follow-up45,112,113,120,179,180. Decisions to continue treatment 
should be based not only on avoiding adverse events but also on a documented improvement 
in hypogonadism symptoms. In fact, owing to the aspecificity of LOH clinical features, their 
improvement upon testosterone therapy is useful information to corroborate the initial 
diagnosis and a reason to continue treatment if adverse events do not occur. As suggested by 
the Endocrine Society guidelines112, symptom monitoring should be performed at 3 months 
after treatment initiation and then annually.
Contraindications for testosterone therapy are locally advanced and metastatic prostate 
cancer. In addition, breast cancer, although rare, is considered a contraindication for this 
therapy45,112,113,120. Likewise, men with an active wish for children should not use 
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exogenous testosterone because it inhibits spermatogenesis owing to suppression of 
gonadotropin secretion and intratesticular testosterone45,112,120,181.
Some evidence suggests that hypogonadal men have an increased risk of CVD182. In this 
context, a recent meta-analysis, including 37 observational studies published between 1988 
and 2017 and enrolling 43,041 men with a mean follow-up of 333 weeks, showed that low 
endogenous testosterone at enrolment predicted overall and cardiovascular mortality and 
cardiovascular morbidity183. With normalization of serum testosterone levels to the 
physiological range, this risk could theoretically decrease, but the causality between low 
testosterone and CVD risk remains unclear. Indeed, many observational studies indicated 
that the normalization of serum testosterone levels to the physiological range can improve 
metabolic risk factors (such as obesity, diabetes and metabolic syndrome)184,185.
Conversely, data from RCTs are still conflicting and not unequivocal186. Moreover, evidence 
mostly obtained from observational studies has suggested a possible increased CVD risk 
related to testosterone therapy187. The CVD risk seems to be higher at the beginning of the 
treatment188. As a sign of conflict and confusion about the position of testosterone treatment 
of LOH, the US FDA cautioned that the benefits and safety of testosterone replacement 
therapy have not been clearly established for the treatment of low testosterone levels in older 
men189. This position has been endorsed by Health Canada190 and by the Australian Society 
of Endocrinology191. By contrast, the European Medicines Agency (EMA), after its own 
review of the available data, did not find sufficient evidence for declaring a testosterone 
replacement therapy-associated cardiovascular risk192. In line with this position, a recent 
meta-analysis including 15 pharmaco-epidemiological trials and 93 RCTs evaluating the 
cardiovascular safety of testosterone replacement treatment concluded that when 
testosterone treatment is correctly applied, it is not associated with an increase in CVD 
risk193. Conversely, the same study documented that an increased cardiovascular risk is 
observed when testosterone treatment is used at dosages higher than those routinely 
recommended193. Debate is still ongoing, and the potential risks of CVD and venous 
thromboembolism associated with testosterone therapy in older men with symptomatic low 
serum testosterone may not be resolved until results of adequately powered RCTs 
specifically designed to this end are available. Such a study (TRAVERSE), sponsored by 
several major drug companies, has recently been initiated in the United States (). Further 
confusion to this issue was added by a very recent Mendelian randomization study from the 
United Kingdom, reporting that the genetically predicted endogenous testosterone levels 
were positively associated with thromboembolism, heart failure and myocardial infarction in 
men194.
Development of polycythaemia during testosterone treatment is relatively common, with 
frequency ranging from 2% to 7% and older men appearing to be at higher risk195. Thus, 
elevated haematocrit is considered a contraindication of testosterone treatment, and 
adherence to the guidelines advising frequent follow-up of haemoglobin or haematocrit is 
important.
Salonia et al. Page 19













Finally, testosterone treatment has been documented to worsen the symptoms of obstructive 
sleep apnoea196, and severe untreated sleep apnoea is included in the contraindications of 
testosterone treatment in ageing men112.
Quality of life
As previously detailed, the EMAS found that the presence of at least three sexual symptoms 
offered the greatest sensitivity and specificity in identifying hypogonadal patients28. The 
association between these sexual symptoms and low testosterone was statistically significant 
(OR 1.71; CI 1.08–2.63) and remained significant after adjustment for age, BMI and 
coexisting illnesses. As discussed in prior sections, sexual dysfunction symptoms are 
probably the symptoms most consistently associated with low serum testosterone in elderly 
men197–199. In this context, a number of meta-analyses demonstrated significant 
improvements in overall erectile function in hypogonadal men initiating testosterone 
therapy. Isidori et al.200, for instance, evaluated 17 placebo-controlled, RCTs of testosterone 
therapy in hypogonadal and eugonadal men. Among those men with low serum testosterone 
levels (<10nmol/l (<288ng/dl)), there were significant improvements with testosterone 
therapy in morning erections, sexual motivation, erectile function, sexual thoughts, sexual 
satisfaction, episodes of successful intercourse and total erections and/or ejaculations200. 
Recently, Corona et al.197 conducted a meta-analysis of RCTs addressing the effects of 
testosterone therapy to treat erectile dysfunction with a mean follow-up of 40.1 weeks197. 
The results demonstrated that testosterone therapy significantly improved erectile function 
compared with placebo (International Index of Erectile Function-Erectile Function domain 
(IIEF-EF) mean difference = 2.31 (95% CI 1.41–3.22)). Patients with more severe 
hypogonadism reported greater improvements in erectile function compared with those with 
milder testosterone deficiency; in this context, the authors found that those men with a serum 
testosterone level <8 nmol/1 (231 ng/dl) had the greatest improvement in erectile function 
following testosterone therapy. According to the TTrial, designed to determine the efficacy 
of testosterone therapy in older hypogonadal men (≥65 years of age)117, testosterone therapy 
was also associated with increased sexual desire according to the Derogatis Interview for 
Sexual Functioning in Men-II (DISF-M-II) (treatment effect 2.93; P <0.001) and increased 
erectile function according to the IIEF (treatment effect 2.64; P <0.001). More precisely, 
20% of men treated with testosterone reported that their sexual desire was much better since 
the beginning of the trial (P <0.001), as compared with <10% of those individuals who 
received placebo instead117. One weakness of the TTrials is their short duration (1 year), and 
it remains unknown whether more promising results could be obtained upon longer 
treatment. Conspicuously, another similar RCT on slightly younger men (TEAAM) showed 
no improvement in sexual function during 3 years of testosterone treatment122. Thus, we can 
conclude that testosterone therapy may improve several aspects of sexual function, but only 
in men with clearly hypogonadal concentrations of testosterone.
Finally, uncontrolled trials have demonstrated that hypogonadal patients not responding to 
PDE5 inhibitors (PDE5Is) may improve their response to PDE5Is after initiating 
testosterone therapy201–203. In the real-world setting, most patients with erectile dysfunction 
will first be prescribed a PDE5I, which is usually effective201; however, if diagnostic criteria 
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suggestive for testosterone deficiency are present, testosterone therapy is the more 
appropriate treatment even in erectile dysfunction patients.
Outlook
Klinefelter syndrome
A longstanding question has been how the presence of an additional X chromosome leads to 
the various features of Klinefelter syndrome. Big data approaches have been used to identify 
new clinical associations with Klinefelter syndrome204, and transcriptomic, epigenomic, 
proteomic and metabolomic approaches have the potential to identify specific pathways 
affected by Klinefelter syndrome205–208. These studies may lead to the development of 
targeted treatments for the many issues associated with Klinefelter syndrome.
When to start androgen treatment in individuals with Klinefelter syndrome is an area of 
active investigation. Whereas frank hypogonadism does not typically become evident until 
late adolescence or adulthood, it has been proposed that boys with Klinefelter syndrome 
have some degree of testosterone deficiency throughout life and that this testosterone 
deficiency may contribute to differences in body composition, learning and behavioural 
challenges and increased risk of CVD. In this context, some studies suggested that early 
testosterone therapy might be beneficial for individuals with Klinefelter syndrome. A 
retrospective analysis including 101 boys with Klinefelter syndrome and micropenis showed 
that early testosterone treatment (from early infancy) improved neuromotor function, speech 
and language, and intellectual and reading function209.
It is important to recognize that the evidence for these effects has largely come from 
observational studies, but randomized trials of early testosterone therapy are now underway 
().
Diagnosis
Currently, the only way to definitively determine whether a child has self-limited CDGP or 
more persistent idiopathic secondary hypogonadism is to monitor over time to determine 
whether the child eventually enters puberty and achieves normal adult reproductive 
endocrine function or not (). Because CDGP is the more common diagnosis, the initial 
approach to management is typically reassurance and watchful waiting, with treatment with 
sex steroids deferred until well after the typical age for entering puberty. A prospective 
method to distinguish constitutional delay from idiopathic secondary hypogonadism would 
allow those with idiopathic secondary hypogonadism, for whom reassurance is 
inappropriate, to receive more timely treatment. However, despite decades of searching, such 
a method does not currently exist210.
Building on the identification of both rare and common genetic variants that contribute to 
constitutional delay and idiopathic secondary hypogonadism, genetic testing may lead to 
earlier diagnosis211. However, this approach may be complicated by genetic overlap between 
these two conditions, and variable penetrance and expressivity may limit the predictive 
power of genetic testing72.
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Provocative stimulation tests offer another potential method to assess future reproductive 
endocrine potential in prepubertal children. Stimulation tests using hCG, GnRH or GnRH 
analogues have been found to lack complete sensitivity or specificity210, but stimulation 
testing using recently identified factors that function upstream of the GnRH neuron, such as 
kisspeptin, may hold promise212.
Treatment
For decades, testosterone therapy has been used to induce pubertal changes in children with 
secondary hypogonadism, with gonadotropin treatment typically reserved for when fertility 
is desired. Recently, there has been renewed interest in the use of gonadotropins as a more 
physiologic method for pubertal induction, as gonadotropin treatment induces testicular 
growth and spermatogenesis in addition to testosterone production in boys104,137,149,213. 
Gonadotropin treatment has also been used during the mini-puberty of infancy214,215. Trials 
directly comparing testosterone to gonadotropin treatment will determine whether the 
benefits of gonadotropin treatment justify the substantially higher cost.
Adults and ageing men
In ‘functional’ hypogonadism (BOX 1), PDE5Is are first-line pharmacotherapy to improve 
erectile dysfunction31. Testosterone therapy can be considered if the previous strategies fail. 
Lifestyle change is also strongly recommended in patients with T2DM, a condition with a 
similar prevalence to hypogonadism, characterized by vague symptoms, including sexual 
dysfunction216. In T2DM, in the presence of defined glucose abnormalities — along with 
lifestyle changes — medical therapy is strongly recommended, although in rare cases an 
‘organic’ alteration is found (1%). Evidence from RCTs indicates that testosterone therapy 
in ‘functional’ hypogonadism is able to improve sexual dysfunction200 and body 
composition186. In addition, meta-analyses of RCTs did not support an association between 
testosterone therapy and an increased cardiovascular risk217–224. One of the main limitations 
in interpreting data from available RCTs is that all currently published controlled studies 
were conducted for a relatively short period of no more than 3 years. Hence, information 
concerning advantages and disadvantages of testosterone medications throughout a longer 
period of time is not yet available. In particular, we need larger and sufficiently powered 
studies with longer duration, and with specific aims, to better clarify hard treatment end 
points. In this framework, multicentre international register studies are welcome ().
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Classification of male hypogonadism
Historically, classification of male hypogonadism has been based on the anatomical 
location of the derangement that leads to testis failure (that is, primary or secondary 
hypogonadism). More recently, it has been proposed to classify hypogonadism according 
to the age of the appearance of the testicular failure and, therefore, to the 
phenotype133,134. Male phenotype can be severely altered if there is a testosterone 
deficiency during early fetal life, whereas an eunuchoid phenotype is often present when 
testosterone deficiency emerges during puberty133,134. When testosterone deficiency 
manifests during adulthood, the phenotype is relatively vague and mostly sexual 
dysfunction is considered to have some specificity45,225. In 2017, Grossmann and 
Matsumoto31 suggested a new classification of male hypogonadism, distinguishing 
functional hypogonadism from its organic counterpart. Organic hypogonadism is 
characterized by any proven pathology affecting the hypothalamic–pituitary–gonadal axis 
and should be treated with the conventional medications (gonadotropins or testosterone) 
accordingly. Functional hypogonadism is based on the absence of any recognized organic 
alterations in the hypothalamic–pituitary–gonadal axis and should be treated, first by 
resolving or improving the associated comorbidities31.
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Types and causes of hypogonadism
Primary hypogonadism
Primary hypogonadism (also known as hypergonadotropic hypogonadism) is caused by 
an inherent defect within the testes. This condition is biochemically characterized by low 
or absent testosterone levels and high gonadotropins levels. Spermatogenesis is usually 
severely impaired and not responsive to hormonal therapy.
Congenital causes
• Trisomies such as Klinefelter syndromea and Down syndrome
• Y-Chromosome microdeletionsa
• Testicular dysgenesis syndrome or other conditions associated with 
cryptorchidisma
• Disorders of sex developmenta
• Myotonic dystrophy (a genetic disorder associated with impaired muscle 
function)a
Acquired causes
• Mumps-related orchitis (or other types of severe infection of the testes)a
• Irradiation or chemotherapya
• Trauma to the testes or castrationa
• Chronic illnesses (such as chronic kidney disease, chronic obstructive 
pulmonary disease or HIV infection)b




Secondary hypogonadism (also known as central hypogonadism or hypogonadotropic 
hypogonadism) is caused by a dysfunction in the hypothalamus and/or the pituitary 
gland. This condition is biochemically characterized by low or inappropriately normal 
gonadotropins levels along with low total testosterone levels. Spermatogenesis is 
impaired but is usually responsive to hormonal therapy.
Congenital causes
• Kallmann syndromea
• Idiopathic secondary hypogonadisma
Acquired causes
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• Pituitary dysfunction due to a tumour, surgery, trauma (for example, those 
causing stalk injury), infection (for example, tuberculosis) or infiltrative 
diseases (such as Langerhans cell histiocytosis)a
• Hypothalamic dysfunction (due to, for example, tumours or intracranial 
masses (such as craniopharyngioma))a
• Hyperprolactinaemiaa
• Chronic conditions (such as type 2 diabetes mellitus, haemochromatosis, 
hepatic steatosis and cirrhosis or coronary artery disease)b
• Drug use (glucocorticoids, opioids, androgens, progestins, oestrogens or 
gonadotropin-releasing hormone analogues)b
• Obesityb
• Malnutrition, wasting or anorexia nervosab
• Excessive exerciseb
• Older age (with associated comorbidities)a,b
aOrganic origin. bFunctional origin.
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When the hormonal deficiency develops during the first trimester of fetal life, the clinical 
manifestation is a disorder of sex development, with a variable degree of hypovi rilization 
of external genitalia. A wide range of rare genetic disorders can be implied that affect 
gonadal development or sex hormone synthesis or action. Overall, the incidence of those 
latter conditions is 1 in 5,000 live male births136,226. Congenital hypogonadotropic 
hypogonadism, either isolated or with deficiency of multiple pituitary hormones (that is, 
combined), is typically established after sex differentiation has occurred (that is, after the 
first trimester). It can present clinically at birth with signs such as micropenis, 
cryptorchidism and/or micro-orchidism or later as delayed puberty17.
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Ontogeny of the HPG axis during fetal development
During the first trimester, the testes drive the virilization of internal and external genitalia 
(that is, the biological development of sex differences) through placental human 
chorionic gonadotropin (hCG)-stimulated androgen secretion by Leydig cells. Regression 
of Müllerian ducts, the anlagen of the uterus and Fallopian tubes occurs in response to 
anti-Müllerian hormone (AMH) secreted by Sertoli cells independently of pituitary 
gonadotropins4. Subsequently, luteinizing hormone (LH) and hCG maintain Leydig cell 
differentiation characterized by the secretion of androgens and insulin-like factor 3 
(INSL3), whereas follicle-stimulating hormone (FSH) regulates Sertoli cells33. 
Androgens, in particular the testosterone metabolite dihydrotestosterone (DHT), are the 
main hormones responsible for the growth of the penis and the scrotum in the second half 
of intrauterine life, and, together with INSL3, they direct the testicular descent227,228. 
Sertoli cells proliferate, therefore, increasing testicular volume. Basal AMH secretion is 
independent of gonadotropins; however, FSH increases AMH output by stimulating 
Sertoli cell proliferation and upregulating AMH expression in Sertoli cells229. FSH also 
induces inhibin B secretion, which exerts negative feedback on FSH at the pituitary level. 
Testosterone elevation during fetal development has also been suggested to play a part in 
human neurobehavioural sexual differentiation; indeed, testosterone potentially has a 
relevant relationship to human neural structure and function in fetal and/or neonatal life4 
as well as neurobehavioural sexual differentiation during early infancy230.
HPG, hypothalamic–pituitary–gonadal.
Salonia et al. Page 39














Treatment of CDGP and persistent hypogonadism in adolescents
Testosteronea
Adverse effects associated with testosterone use include erythrocytosis, weight gain, 
prostate hyperplasia and transaminitis; high doses can cause premature epiphyseal 
closure. Testosterone should be used with caution when bone age is <10 years. Anabolic 
steroids are not recommended for the induction of secondary sexual characteristics.
• Testosterone esters (that is, testosterone enanthate, testosterone cypionate and 
testosterone propionate): these formulations are usually administered as 
intramuscular injections, but subcutaneous use is an emerging option. 
Treatment can be associated with local adverse effects (such as pain, 
erythema, inflammatory reaction and sterile abscess); priapism can occur in 
patients with sickle cell disease.
• Testosterone undecanoate: data and experience of the use of this formulation 
in constitutional delay of growth and puberty (CDGP) are limited.
• Testosterone gel: data and experience of the use of this formulation in CDGP 
are limited. The gel can cause local irritation, and close skin contact with 
others should be avoided after applying to prevent transfer of medication.
• Testosterone nasal gel: data and experience of the use of this formulation in 
CDGP are lacking. Formulation requires multiple doses per day per nostril, 
but the lack of risk of secondary transference is an advantage.
Pulsatile GnRH
This treatment is usually reserved for instances of persistent hypogonadotropic 
hypogonadism due to hypothalamic defects. However, it is sometimes used for treatment 
of CDGP to induce testicular maturation and when fertility is desired. Pulsatile 
gonadotropin-releasing hormone (GnRH)b is the most physiologic form of replacement 
therapy if the primary defect affects the hypothalamus. This formulation is administered 
via subcutaneous pump and requires extensive experience.
hCG combined with recombinant FSH or purified hMG
This treatment is usually reserved for instances of persistent hypogonadotropic 
hypogonadism due to hypothalamic or pituitary defects. However, it is sometimes used 
for treatment of CDGP to induce testicular maturation and when fertility is desired. The 
treatment includes subcutaneous or intramuscular human chorionic gonadotropin (hCG) 
injections combined with subcutaneous recombinant human follicle-stimulating hormone 
(FSH) injections or human menopausal gonadotropin (hMG), which contains equal 
amount of FSH and luteinizing hormone. In secondary hypogonadism with prepubertal 
onset, FSH needs to be included to induce testicular growth and spermatogenesis.
aTestosterone esters are the recommended first-line treatment for CDGP in most cases.
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bInduction of fertility following treatment with GnRH may be less successful in men who 
have lower baseline testicular volumes, have previously received testosterone treatment 
and have not previously received treatment with GnRH or gonadotropins29,46–48. Because 
of these findings, recent studies have explored use of alternative methods to induce 
puberty with the ultimate question being whether these approaches increase subsequent 
fertility49,50. Box based on data originally presented in REF.105.
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Fig. 1 |. The hypothalamic–pituitary–gonadal axis.
Both testosterone synthesis and male fertility result from the delicate coordination 
throughout the hypothalamic–pituitary–gonadal axis, thereby ensuring normal testicular 
function1. Gonadotropin-releasing hormone (GnRH) stimulates the release of luteinizing 
hormone (LH) from the pituitary gland. This triggers the Leydig cells within the testes to 
respond by producing adequate levels of testosterone, which, in turn, exerts negative 
feedback control on the hypothalamus and pituitary gland. Likewise, GnRH stimulates the 
release of follicle-stimulating hormone (FSH) from the pituitary gland. This triggers and 
sustains the spermatogenesis within the exocrine part of the testes. The testes contribute 
>95% of total circulating testosterone in the postpubertal male; testosterone is secreted into 
the circulation down a concentration gradient, where it equilibrates between protein-bound 
(98%) and free hormone (1–2%) fractions. Circulating testosterone and other sex hormones 
are bound either to low-affinity, high-availability proteins (primarily albumin) or to the high-
affinity glycoprotein sex hormone-binding globulin (SHBG). These binding proteins play an 
important part in regulating the transport, distribution, metabolism and biological activity of 
the sex hormones231,232. Conditions that alter SHBG levels (for instance, ageing, obesity, 
insulin resistance and liver disease) influence free testosterone levels. The free hormone 
fraction is postulated to be the biologically active form of testosterone1,231,232. Testosterone 
secretion varies throughout the day and is usually the highest in the morning. Hence, 
samples to determine testosterone levels need to be taken in the morning. Figure adapted 
from REF.233, Springer Nature Limited.
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Fig. 2 |. Anatomical changes and serum hormone levels associated with male sex determination 
and maturation.
In the fetal period, testicular hormones begin to be secreted independently of fetal pituitary 
gonadotropins in the first trimester of fetal life and drive fetal differentiation of the genitalia. 
In the second and third trimesters, growth of the genitalia and testicular descent are 
stimulated by androgen secretion dependent on fetal luteinizing hormone (LH). In the 
postnatal period, testicular volume increases during childhood owing essentially to Sertoli 
proliferation. After the postnatal activation in the 0–6-month period (usually called ‘mini-
puberty’), serum levels of gonadotropins and testosterone (T) decline, but those of the 
Sertoli cell markers anti-Mullerian hormone (AMH) and inhibin B persist at clearly 
detectable levels. During puberty, testicular volume increases dramatically owing to 
spermatogenic development, secondary to gonadotropin and T action. Sertoli cell markers 
show opposite profiles: AMH is inhibited by T whereas inhibin B is upregulated by follicle-
stimulating hormone (FSH) and germ cells. INSL3, insulin-like factor 3; O, testicular 
volume measured by comparison to Prader’s orchidometer; US, testicular volume measured 
by ultrasonography.
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Fig. 3 |. Pathophysiology of hypogonadism.
Hypogonadism may be caused by a primary testicular pathology (primary hypogonadism, 
otherwise known as hypergonadotropic hypogonadism, which is defined as low testicular 
hormones, with high gonadotropins) resulting from malfunction at the level of the testes due 
to a genetic cause, injury, inflammation or infection (panel a). Conversely, central defects of 
the hypothalamus or the pituitary gland lead to secondary hypogonadism (also called central 
hypogonadism or hypogonadotropic hypogonadism, which is defined as low testicular 
hormones, with low or normal gonadotropins), which is most often caused by genetic 
defects, neoplasm or infiltrative disorders (panel b). FSH, follicle-stimulating hormone; 
GnRFI, gonadotropin-releasing hormone; LH, luteinizing hormone. Adapted with 
permission from REF.31, Oxford University Press.
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Fig. 4 |. Pathophysiology of congenital secondary hypogonadism.
Genes associated with congenital secondary hypogonadism. GnRH, gonadotropin-releasing 
hormone.
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Fig. 5 |. Relationship between age, BMI and reproductive hormones.
The graphs present mean levels of total and calculated free testosterone, luteinizing hormone 
(LH) and sex hormone-binding globulin (SHBC). a | Total testosterone is reduced in 
overweight and obese men compared with nonobese men at all ages. b | Free testosterone, 
similar to total testosterone, is reduced in overweight and obese men compared with 
nonobese men at all ages. c | LH increases with age but is not associated with body mass 
index (BMI). d | SHBC increases with age. For total testosterone and SHBC, no interaction 
between BMI and age were found, whereas free testosterone showed an interaction between 
BMI and age. The data were derived from a cohort of 3,220 men aged 40–79 years recruited 
in the European Male Ageing Study (EMAS) study. Shaded areas and vertical lines represent 
the 95% CI. Adapted with permission from REF.76, Oxford University Press.
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Fig. 6 |. Diagnostic algorithm for hypogonadism in pubertal age.
Diagnostic flowchart in a boy presenting with no signs of pubertal development by 14 years 
of age. Tests mentioned may help to distinguish among and/or confirm diagnoses, but the 
full battery is not recommended or warranted in all cases and may not lead to a conclusive 
diagnosis. The main text describes considerations regarding test use. AMH, anti-Müllerian 
hormone; CDGP, constitutional delay of growth and puberty; DHEAS, 
dehydroepiandrosterone; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing 
hormone; IGF1, insulin-like growth factor 1; LH, luteinizing hormone; T4, thyroxine; TSH, 
thyroid-stimulating hormone.
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Table 2 |
Laboratory cut-off values for biochemical late-onset hypogonadism
Guideline Total testosterone; nmol/l (ng/ml) Calculated free; testosterone 
pmol/l (pg/ml)
Ref.
American Urological Association 10.4 (3.0) NA 234
British Society for Sexual Medicine • Mild: 12.1 (3.5)




Canadian Endocrine Society Depending on reference values in local 
laboratory
NA 235
European Association of Urology 12.1 (3.5) 243 (70) 120
Endocrine Society 9.2 (2.64) NA 112
International Society for Sexual Medicine 12.0 (3.5) NA 45
International Society for the Study of the Aging 
Male
12.1 (3.5) 243 (70) 236
NA, not applicable.
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